Human antibodies to the human glucagon receptor and methods of use thereof
First Claim
1. An isolated human antibody or antigen-binding fragment thereof that specifically binds human glucagon receptor (hGCGR), wherein the antibody comprises the complementarity determining regions (CDRs) of a heavy chain variable region (HCVR), wherein the HCVR has an amino acid sequence as set forth in SEQ ID NO:
- 86; and
the CDRs of a light chain variable region (LCVR), wherein the LCVR has an amino acid sequence as set forth in SEQ ID NO;
88.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention provides antibodies that bind to the human glucagon receptor, designated GCGR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GCGR. The antibodies of the invention are useful for lowering blood glucose levels and blood ketone levels and are also useful for the treatment of diseases and disorders associated with one or more GCGR biological activities, including the treatment of diabetes, diabetic ketoacidosis and long-term complications associated with diabetes, or other metabolic disorders characterized in part by elevated blood glucose levels.
-
Citations
17 Claims
-
1. An isolated human antibody or antigen-binding fragment thereof that specifically binds human glucagon receptor (hGCGR), wherein the antibody comprises the complementarity determining regions (CDRs) of a heavy chain variable region (HCVR), wherein the HCVR has an amino acid sequence as set forth in SEQ ID NO:
- 86; and
the CDRs of a light chain variable region (LCVR), wherein the LCVR has an amino acid sequence as set forth in SEQ ID NO;
88. - View Dependent Claims (2, 3, 4, 6, 7, 10, 11, 12, 13, 14, 15, 16, 17)
- 86; and
-
5. An isolated antibody or antigen-binding fragment thereof that specifically binds human glucagon receptor (hGCGR), wherein the antibody comprises:
-
(a) a HCDR1 domain having an amino acid sequence as set forth in SEQ ID NO;
72;(b) a HCDR2 domain having an amino acid sequence as set forth in SEQ ID NO;
74;(c) a HCDR3 domain having an amino acid sequence as set forth in SEQ ID NO;
76;(d) a LCDR1 domain having an amino acid sequence as set forth in SEQ ID NO;
80;(f) a LCDR2 domain having an amino acid sequence as set forth in SEQ ID NO;
82; and(g) a LCDR3 domain having an amino acid sequence as set forth in SEQ ID NO;
84. - View Dependent Claims (8, 9)
-
Specification